Wiebe J, Hofmann FJ, West N, et al. - Analysis of EAC (European ABSORB Consortium) provided reasonable real-world clinical outcome data following bioresorbable vascular scaffolds (BVS) implantation for coronary artery disease treatment, but also revealed a high rate of scaffold thrombosis.

• Data were obtained from the European ABSORB Consortium.

• Overall 10,312 patients (mean age 58.4 ± 11.4 y) who received BVS implantation were included, and 12-month follow-up was complete in 95.5% of patients.

• Occurrence of primary endpoint of target lesion failure was evident in 3.6% at 12 months.

• Cardiac death, target-vessel myocardial infarction and target-lesion revascularization occurred in 1.2%, 1.8%, and 2.6%, respectively.

• Definite/probable scaffold thrombosis (ST) rate was reported to be 1.7%.

• Independent predictors of ST were absence of predilatation, cessation of dual antiplatelet therapy and scaffold diameter below 3 mm.